-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Solid Tumor Drug Details: HBM-1020 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Metastatic Colorectal Cancer Drug Details: HBM-1020 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Metastatic Renal Cell Carcinoma Drug Details: HBM-1020...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – UCART20x22 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - UCART20x22 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. UCART20x22 in Follicular Lymphoma Drug Details: Gene therapy is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-500 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-500 in Malignant Mesothelioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-500 in Malignant Mesothelioma Drug Details: TAK-500 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-7008 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. HBM-7008 in Solid Tumor Drug Details: Bi-specific monoclonal antibody is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-4003 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-4003 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Porustobart in Metastatic Melanoma Drug Details: HBM-4003 is under development for...
-
Product Insights
NewAdrenal Gland Disorders – Drugs In Development, 2024
Empower your strategies with our Adrenal Gland Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Adrenal gland disorders comprise various conditions impacting the vital endocrine organs positioned above each kidney. Diagnosis involves diverse tests tailored to symptoms and health history. Blood, urine, or saliva tests are employed to assess hormone levels, while imaging studies like x-rays, CT scans, or MRI scans are ordered to detect tumors. This comprehensive diagnostic approach assists healthcare providers in identifying and...
-
Product Insights
NewPolycystic Ovarian Syndrome – Drugs In Development, 2024
Empower your strategies with our Polycystic Ovarian Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Polycystic ovarian syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen, and polycystic ovaries. The main risk factor for PCOS is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy. The Polycystic Ovarian Syndrome drugs in development...
-
Product Insights
NewCongenital Adrenal Hyperplasia (Adrenogenital Syndrome) – Drugs In Development, 2024
Empower your strategies with our Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) – Drugs In Development, 2024 report and make more profitable business decisions. Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease emerging from mutations of genes for enzymes that lead to the biochemical steps of production of glucocorticoids, mineralocorticoids, or sex steroids from cholesterol by the adrenal glands. This condition involves the excessive or deficient production of sex steroids that can alter the development of primary or secondary sex characteristics in some...